Direct cardioprotective effect of dexmedetomidine against ischemia/reperfusion injury in hypertensive hypertrophied myocardium
| Project/Area Number |
26861237
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Anesthesiology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HIRATA Naoyuki
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | デクスメデトミジン / 虚血再灌流障害 / 高血圧 / イミダゾリン / 肥大心筋 |
|---|
| Outline of Final Research Achievements |
The present study revealed that dexmedetomidine maintains the direct cardioprotective effect against ischemia/reperfusion injury in hypertensive hypertrophied myocardium via different mechanism from normal healthy heart. Dexmedetomidine protects normal healthy heart through eNOS phosphorylation via alpha2 adrenoreceptor. On the other hand, the results of the present study revealed that the cardioprotective effect of dexmedetomidine in hypertensive hypertrophied myocardium is via imidazoline 1 receptor, which remains in normal expression level, not via alpha2 adrenoreceptor, which is up-regulated in hypertrophied myocardium. Furthermore, our data indicated that eNOS phosphorylation does not contribute to the cardioprotective effect of dexmedetomidine in hypertensive hypertrophied myocardium.
|
Report
(4 results)
Research Products
(2 results)
